Floatz logo

Eudemine Injection

Digestive System Neuroendocrine Neoplasm

University of Maryland, BaltimoreSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Digestive System Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BBB
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
Novartis Pharmaceuticals
Phase 3BB
Everolimus
RayzeBio, Inc.
Phase 3BB
Edotreotide
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B
Lanreotide
RayzeBio, Inc.
Phase 3B

View all 31 →

Same molecule, other indications

Eudemine Injection is also rated in:

craniopharyngiomaDormant
BB
Indicative · Phase 3
64 / 100
View asset →
neuroendocrine disorderDormant
BB
Indicative · Phase 3
64 / 100
View asset →
hyperinsulinismActive
B
Indicative · Phase 2
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →